Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on March 15, 2019, covering events that occurred on March 14, 2019. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The report focuses exclusively on corporate governance and capital structure modifications.
Material Changes
On March 14, 2019, the Company amended the Certificate of Designation for its Series A Convertible Participating Preferred Stock with the consent of the sole holder. Key changes include:
- Conversion Price Adjustment: The conversion price was reduced from $2.775 per share to $0.2775 per share.
- Voting Rights: Holders of Series A Preferred Stock retain voting rights on an as-converted basis, subject to limitations under Nasdaq Listing Rule 5640.
- Redemption Threshold Adjustment: The 30-day volume-weighted average price (VWAP) threshold for both the Company's optional redemption right and the preferred stockholders' mandatory redemption right was lowered from $15.00 to $1.50.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the specific amendment details. The amendment became effective immediately upon filing with the Secretary of State of Delaware.
Investor Verification Checklist
- Verify the impact of the 10x reduction in conversion price on the Company's capitalization table and potential dilution to common shareholders.
- Confirm the current 30-day VWAP of the Company's common stock relative to the new $1.50 redemption threshold.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for additional covenants or conditions not summarized in the 8-K.
- Assess the implications of the voting rights limitation under Nasdaq Listing Rule 5640 on future corporate actions.